Bolt Biotherapeutics, Inc.

BOLT Nasdaq SEC CIK 1641281
Follow Bolt Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$4.4M +38.1% vs same quarter last year
EPS, diluted −$2.25 +39.5% vs same quarter last year
Operating cash flow −$3.1M +68.4% vs same quarter last year
Revenue by quarter
$0
$1.2M
$1.8M
$2.2M
$2.5M
$26K
$5K
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$7.7M−$33.4M
FY24$7.7M−$63.1M
FY23$7.9M−$69.2M
FY22$5.7M−$88.1M
FY21$1.3M−$98.6M
FY20$231K−$60.7M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−469.3%−433.7%
FY24−949.9%−820.8%
FY23−967.4%−878.6%
FY22−1576.6%−1537.8%
FY21−7364.1%−7824.7%
FY20−21290.9%−26289.2%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$39.9M
FY24−$61.3M
FY23−$69.7M
FY22−$78.5M
FY21−$59.4M
FY20−$50.6M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Bolt Biotherapeutics
  • Healthcare median
−30000%−20000%−10000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBolt BiotherapeuticsHealthcare median
FY25−433.7%−30.6%
FY24−820.8%−47%
FY23−878.6%−58%
FY22−1537.8%−80.4%
FY21−7824.7%−71.8%
FY20−26289.2%−62.2%
FY19-−46.2%